Innova Captab Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a significant 30.5% year-on-year growth in revenue from operations for Q2 FY27, reaching ₹496.3 crore. EBITDA also saw a healthy increase of 29.2% to ₹72.4 crore, with PAT growing by 43.0% to ₹42.4 crore.
Innova Captab Reports Robust Financial Performance for Q2 FY27
Innova Captab Limited has declared its unaudited financial results for the second quarter and the first half of the financial year ending September 30, 2026. The company demonstrated strong growth across key financial metrics, underscoring its robust business momentum.
Q2 FY27 Performance Highlights
For the second quarter of FY27, Innova Captab reported a substantial 30.5% increase in revenue from operations compared to the same period last year, amounting to ₹496.3 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 29.2% to ₹72.4 crore. The Profit After Tax (PAT) for the quarter surged by 43.0% to ₹42.4 crore. The EBITDA margin stood at 14.6%, while the PAT margin was 8.5%.
H1 FY27 Performance Overview
The company also showcased strong performance for the half year ended September 30, 2026. Revenue from operations climbed by 32.1% to ₹967.2 crore. EBITDA saw a growth of 31.0%, reaching ₹147.5 crore. PAT for the half year increased by 42.6% to ₹86.5 crore. The EBITDA margin for the half year was 15.3%, and the PAT margin was 8.9%.
Management Commentary
Mr. Vinay Lohariwala, Managing Director of Innova Captab Limited, commented on the results, stating, “Innova Captab Limited delivered a strong performance in Q2FY27, with revenue growing 30.5% YoY to ₹496.3 crore, EBITDA increasing 29.2% to ₹72.4 crore and PAT growing 43.0% to ₹42.4 crore. The performance underscores the continued strength of our diversified business model and disciplined execution across our business operations.”
He further added that the company continues to witness healthy business momentum across its CDMO and Branded Generics businesses. Innova Captab remains committed to strengthening its CDMO positioning, expanding its branded generics presence, and ramping up manufacturing capacities, confident in sustaining long-term growth.
Source: BSE
